During Thursday’s Morning trade, Shares of Natera, Inc. (NASDAQ:NTRA), surged 22.56% to $22.06.
Natera, declared the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price to the public of $18.00 per share before underwriting discounts, commissions and estimated expenses. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.
The offering is predictable to close on July 8, 2015, subject to customary closing conditions.
Morgan Stanley, Cowen and Company, and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Baird and Wedbush PacGrow are acting as co-managers for the offering.
Natera is a leading genetic testing company that develops non-invasive methods for analyzing DNA. Natera’s team of PhDs and engineers uses its complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions. Natera’s aim is to change the administration of genetic disease worldwide, giving patients and providers essential health information.
Shares of Xoom Corporation (NASDAQ:XOOM), inclined 22.68% to $25.40, during its current trading session.
PayPal, Inc. and Xoom Corporation, declared a definitive agreement under which PayPal will acquire Xoom for $25 per share in cash or an approximate $890 million enterprise value. The transaction represents a premium of 32% over Xoom’s three-month volume-weighted average price and was unanimously approved by the Boards of Directors of both companies, as well as the Board of eBay Inc., PayPal’s parent company.
Dan Schulman, President of PayPal, said, “Expanding into international money transfer and remittances aligns with our planned vision to democratize the movement and administration of money. Acquiring Xoom allows PayPal to offer a broader range of services to our global customer base, enhance customer engagement and enter an important and growing adjacent marketplace. Xoom’s presence in 37 countries – in particular, Mexico, India, the Philippines, China and Brazil – will assist us accelerate our expansion in these important markets.”
John Kunze, President and Chief Executive Officer of Xoom, remarked, “Becoming part of PayPal represents an exciting new chapter for Xoom, which will assist accelerate our time-to-market in unserved geographies and expand the ways we can innovate for customers. Being part of a larger, global organization will assist us deliver the best possible experience to our customers, while maximizing value for our shareholders.”
Xoom Corporation provides digital consumer-to-consumer online money transfers services worldwide. The company offers money transfer services over the Internet or through a mobile device on its Website at xoom.com, or through its mobile application, the Xoom App. Its customers send money to family and friends from the United States to 32 countries.
Finally, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), gained 8.03%, and is now trading at $3.51.
Sunesis Pharmaceuticals, declared that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8th at 9:00 AM Eastern Time at Le Parker Meridien Hotel in New York City.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has accomplished a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
